<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Loop diuretic doses for adult patients with common causes of edema</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Loop diuretic doses for adult patients with common causes of edema</h1>
<div class="graphic"><div class="figure"><div class="ttl">Loop diuretic doses for adult patients with common causes of edema</div><div class="cntnt"><table cellspacing="0"><colgroup span="10" width="10%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2"> </td> <td class="subtitle1" colspan="3">Starting dose<br/> (oral or intravenous*)</td> <td class="subtitle1" colspan="3">Maximum effective dose<sup>¶</sup><br/> (higher individual doses or more frequent dosing intervals are unlikely to produce substantial additional diuresis)<sup>Δ</sup></td> <td class="subtitle1" colspan="3">Maximal recommended daily dose<sup>¶</sup><br/> (greater daily total doses are associated with a risk for toxicity)</td> </tr> <tr> <td class="subtitle2">Furosemide</td> <td class="subtitle2">Bumetanide</td> <td class="subtitle2">Torsemide</td> <td class="subtitle2">Furosemide</td> <td class="subtitle2">Bumetanide</td> <td class="subtitle2">Torsemide</td> <td class="subtitle2">Furosemide</td> <td class="subtitle2">Bumetanide</td> <td class="subtitle2">Torsemide</td> </tr> <tr> <td><strong>Heart failure<sup>◊</sup></strong></td> <td>20 mg once or twice daily</td> <td>0.5 mg once or twice daily</td> <td>5 mg once daily</td> <td>80 mg 3 times daily</td> <td>3 mg 3 times daily</td> <td>50 mg twice daily</td> <td>600 mg</td> <td>10 mg</td> <td>200 mg</td> </tr> <tr> <td><strong>Cirrhotic ascites<sup>§</sup></strong></td> <td>40 mg once or twice daily</td> <td>1 mg once or twice daily</td> <td>10 mg once daily</td> <td>40 mg 3 times daily</td> <td>1 mg 3 times daily</td> <td>20 mg twice daily</td> <td>160 mg</td> <td>4 mg</td> <td>40 mg</td> </tr> <tr> <td><strong>Nephrotic syndrome</strong></td> <td>40 mg once or twice daily</td> <td>1 mg once or twice daily</td> <td>10 mg once daily</td> <td>120 mg 3 times daily</td> <td>3 mg 3 times daily</td> <td>50 mg twice daily</td> <td>600 mg</td> <td>10 mg</td> <td>200 mg</td> </tr> <tr> <td><strong>Chronic kidney disease<sup>¥</sup></strong></td> <td>‡</td> <td>‡</td> <td>‡</td> <td>200 mg 3 times daily</td> <td>10 mg 3 times daily</td> <td>100 mg twice daily</td> <td>600 mg</td> <td>10 mg</td> <td>200 mg</td> </tr> <tr> <td><strong>Acute kidney injury</strong></td> <td>80 mg once or twice daily</td> <td>2 mg once or twice daily</td> <td>20 mg once daily</td> <td>500<sup>†</sup> mg once</td> <td>Not reported</td> <td>Not reported</td> <td>600 mg</td> <td>Not reported</td> <td>Not reported</td> </tr> </tbody></table></div><div class="graphic_footnotes">* Refer to UpToDate topics on the maximum effective dose and major side effects of loop diuretics for details.<br/>¶ Dose is delivered intravenously.<br/>Δ More aggressive regimens have been shown to be safe and effective for acute decompensated heart failure. Refer to UpToDate topics on the use of diuretics in patients with heart failure for details.<br/><font class="lozenge">◊</font> Guidelines from American College of Cardiology/American Heart Association<sup>[1]</sup> recommend furosemide and bumetanide starting daily or twice daily and torsemide starting daily. Similar guidelines are available from the European Society of Cardiology<sup>[2]</sup>. Note that higher doses may be useful in acute decompensated heart failure.<br/>§ In most patients with cirrhosis, furosemide (or equivalent) should be combined with spironolactone at a ratio of 40 mg furosemide to 100 mg of spironolactone; the dosing ratio should be adjusted based upon the plasma potassium concentration. Refer to UpToDate topics on initial therapy of ascites for details.<br/>¥ Chronic kidney disease alone typically does not cause edema but complicates the treatment of other edematous syndromes. In this situation, the presence of chronic kidney disease should guide dosing. Refer to UpToDate topics on the maximum effective dose and major side effects of loop diuretics for details.<br/>‡ Initial diuretic doses for patients with chronic kidney disease depend on its stage but are generally higher than those given for patients with heart failure or cirrhosis.<br/>† High doses of furosemide (500 mg) may be effective, but most authorities now avoid such high doses and, instead, recommend a single trial with a lower starting dose.</div><div class="graphic_reference">References:

	<ol>
<li>Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.</li>
<li>Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21:137.</li>
</ol>

	Courtesy of David H Ellison, MD, FASN, FAHA.</div><div id="graphicVersion">Graphic 120718 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
